Sponsored Post

Here’s how Bellicum Pharmaceuticals answers call to change Big Pharma

This post is sponsored by eyeforpharma. The definition of pharma needs to be rewritten. Why? […]

eyeforpharma logoThis post is sponsored by eyeforpharma.

The definition of pharma needs to be rewritten. Why?

Your pharma company is not just drug developer anymore. In the new consumer-driven health economy, pharma’s new role is that of a health care player.

Thus, the industry needs to find the next commercial model that guarantees their organization as the trusted partner that embeds a patient-centered approach.

Discussion, however, is not the same as action. We can talk all we want about how the patient comes first, but if pharma continues to stick with a worn-out business model that only promotes the product, all this chatter surrounding customer centricity and patient value is just hot air.

Keeping in line with the urgency to take action, a true change maker in pharma decided to speak out. eyeforpharma sat down with Peter Hoang, Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals, to discuss value-added partnerships with health systems. You can view the interview here: http://goo.gl/kNG4ia

Peter Hoang will be among the key influencers taking the stage at the eyeforpharma Philadelphia 2016 summit (May 2-3). He will discuss specifics on developing a partnership with health systems and payers to add value to your sales force, providing next steps to revamp your own commercial model.

Other industry executives leading the charge at this unmissable pharma-stakeholder summit are Christi Shaw, US Country Head at Novartis, Paul Perreault, CEO of CSL Behring, Ramona Sequeira, US President at Takeda, and Murray Stewart, Chief Medical Officer of GSK. Only the best in pharma are taking the initiative to come together and embrace commercial change in a consumer-driven health economy.

The industry will be held accountable. Case studies from Merck, Novartis, AstraZeneca, Eli Lilly, Pfizer, and UCB (just to name a few) will guarantee that pharma companies indeed have ways to establish partnerships that promote the end user: the patient.

eyeforpharma’s goal for 2016 and beyond is to do away with the empty promises. C-level execs will both accept the challenge of prioritizing customer partnerships and deliver concrete next steps for promoting the patient voice. Rather than wax philosophical about theoretical solutions to problems we already know exist, eyeforpharma Philadelphia’s attendees will push the commercial model beyond the tactics of the past. We will do away with reach and frequency and rethink our organizational model to put patients first.

Those that attend eyeforpharma Philadelphia will lead pharma on the path to once again become relevant and revered. You can join the movement, too.

Shares0
Shares0